



Are you ready for the Golden  
Years?

# Intro to Geriatric Psychopharmacology

ALAN "TONY" AMBERG, MS MSN APRN PMHNP-BC

MELISSA VITALE, RN BSN, PSYCHIATRIC APRN TRAINEE

SUZANA NIKOVIC, RN BSN, AGNP TRAINEE



Aged 65 and over will increase substantially between 2010 and 2030, **reaching 72 million in 2030, compared to 35 million in 2000**

## Life span at birth:

- i. 1900 – 47.3 years
- ii. 1950 – 68.4 years
- iii. 2012 – 78.2 years
- iv. 2050 – 84.5 years?

- ▶ Caucasian life span > African American (5 years for men, 3.4 years for women)
  - ▶ “The Hispanic Paradox” – Latinos have lower mortality than Caucasians
- ▶ Adults with <12 years of education have life spans in the 1950s and 1960s
- ▶ **Whites with 13+ years of education compared to African-Americans with <12 years of education can live 16+ years longer**



# Who's going to take care of them?

- ▶ Roughly 1k geropsychiatrists (2.6%) of psychiatric workforce or 1:72,000
- ▶ Psychiatrist workforce has shrunk (2003) 37,968 to (2013) 37,889. By 2025 the projected shortage of psychiatrists will be between 6,000-15,000.
- ▶ Currently **55% of all US counties have no psychiatrists** – 77% have severe shortages
- ▶ Psychiatric reimbursement does not cover the cost of inpatient geropsych-- in many cases leading to units closing
- ▶ **40% of psychiatrists have stopped taking insurance and some or all of their practice is cash only** (National Council for Behavioral Health, 2017)
- ▶ **60% of psychiatrists are 55 or older, 27% are 65 or older** (Merritt Hawkins, 2017)
- ▶ Starting in roughly 10 years, about **half of the current Masters or Doctorally-prepared psych RNs will begin to retire**
- ▶ **Currently adding about 1,500 new Psych NPs a year**



# How prevalent is psychiatric disorder in the elderly?

- ▶ Wave 2 of the NESARC, conducted by the National Institute on Alcohol Abuse and Alcoholism - 2004/2005
- ▶ Total sample =34,653.
  - ▶ Compared young-old (55-64; N+5,135)
  - ▶ middle-old (65-74; N+3,634)
  - ▶ old-old (75-84; N+2,673)
  - ▶ oldest-old (85+; N+870) age groups
- ▶ LIMITATION: this is community-dwelling adults and does not cover institutionalized adults
- ▶ In the total sample (including 55-64)
  - ▶ “Any past-year mood disorder was 6.8%, the most prevalent of which was major depression (5.6%)”
  - ▶ “Any past-year anxiety disorder (11.4%), the most prevalent of which was specific phobia (5.8%). Any past-year substance use disorder among older adults was 3.8%.”
  - ▶ “A total of 14.5% of older adults met criteria for at least one personality disorder, the most prevalent of which was obsessive-compulsive personality disorder (6.5%)”



# How prevalent?

65-74 (n=5,135)

Any mood disorder –  
5.68%

Any anxiety disorder-  
9.45%

Any substance use  
disorder- 2.57%

Any personality disorder-  
13.24%

P<0.001

75-84 (n=2,673)

Any mood disorder –  
8.48%

Any anxiety disorder-  
4.40%

Any substance use  
disorder- 1.73%

Any personality disorder-  
10.36%

P<0.001

85+ (n=870)

Any mood disorder –  
4.23%

Any anxiety disorder-  
7.15%

Any substance use  
disorder- 0.15%

Any personality disorder-  
10.67%

P<0.001



# Practice Recommendation

Screen patients with **any chronic health condition** for depression, especially patients with diabetes, cardiovascular disease, or chronic pain as depression

Remember the presence of any psychiatric disorder or SUD **will greatly impact on all treatment recs and ability to follow them**

US Preventive Services Task Force. Screening for depression: recommendations and rationale. *Ann Intern Med.* 2002;136(10):760-764

AAFP Approved source: Institute for Clinical Systems Improvement

Website: [http://www.icsi.org/depression\\_5/depression\\_\\_major\\_\\_in\\_adults\\_in\\_primary\\_care\\_3.html](http://www.icsi.org/depression_5/depression__major__in_adults_in_primary_care_3.html)

Strength of Evidence: Grade A (randomized, controlled trials)



# Is it really a psychiatric issue or is it...?

- 55%-98% OF OLDER PEOPLE HAVE TWO OR MORE CHRONIC DISEASES
- POLYPHARMACY = FOUR OR MORE MEDICATIONS
  - Both prescribing multiple drugs appropriately or too many drugs inappropriately.
  - What's inappropriate? – Complex medication regimens, Dose form, Dosing frequency
- POLYPHARMACY HAS BEEN ASSOCIATED WITH:
  - Non-Adherence
  - Mental Health problems
    - Sedation
    - Poor memory
    - Lack of energy
    - Poor cognition



# Reducing polypharmacy

- ▶ Use Motivational interviewing to assist patient in finding intrinsic motivation to adhere
- ▶ Choose drugs with the lowest adverse effect profile
- ▶ Maximize one drug before moving to another
- ▶ Decrease the Regimen complexity, and ensure ease of handling
- ▶ Review patient co-morbidities and medication profile for potential drug-drug interactions
- ▶ Frequent follow-up with limited refills
- ▶ Medication review and schedule at every visit



# Other physiologic problems that mimic psychiatric issues...

- ▶ Cancer
- ▶ Delirium
- ▶ Head injury or CVA
- ▶ Infections
- ▶ Vitamin B12 deficiency
- ▶ Hypothyroid
- ▶ Beta-Blockers
- ▶ Insomnia
- ▶ Sedating medications
- ▶ Psychosocial



# Depression and Geriatrics

## -- it's one in 20 of your patients

- ▶ Studies suggest that 5-20% of older adults in the United States experience depression.
- ▶ Most geriatric patients tend to prefer psychotherapy over psychopharmacotherapy, although psychotherapy is rarely offered.
  - ▶ Especially if patients are struggling with illness, death of friends, loneliness, financial issues
- ▶ Antidepressants are weak drugs and work over time, they require monitoring and titration
  - ▶ A fair trial is when the med is optimized and checked for six weeks
  - ▶ Patients need education/support or they will not keep taking it

Karel, M. J., Gatz, M., & Smyer, M. A. (2012). Aging and mental health in the decade ahead: What psychologists need to know. *American Psychologist*, 67(3), 184-198. doi:10.1037/a0025393



# Suicide - How pervasive and who?

- ▶ **650,000 ED visits for self-harm & about 41,000 deaths:** median 12:1 ratio for self-harm vs. completion (teens 25:1 & **elderly 4:1**)
- ▶ **Men complete suicide/ Women attempt it :** in 2013 78% of completers were men; three-fourths of attempts by women
- ▶ **Caucasian males** account for 70% of all suicides in 2013
- ▶ **Firearms** were implicated in 52% of deaths (2013)
- ▶ **Highest risk is not the ages you think:** 45-64 (19.1/100,000) **and >85 (18.6/100,000)** – teens 15-24 are much lower (10.9/100,000)
- ▶ **The rate is stable:** suicide rate 12.5/100,000 in 1985 – 12.6/100,000 in 2013 (some dip in the 90s, never less than 10/100,000)

(Violence Prevention, 2016)



# Choosing Antidepressants

## Start low – go slow

A medication with low potential for short-term weight loss may be more appropriate for frail patients.

- ▶ Citalopram/ Escitalopram: Most studied and highly effective in the elderly.
  - ▶ Citalopram doses should be limited to a maximum of 20 mg/day because QT prolongation is a concern.]
- ▶ Sertraline - safest for complex co-morbid patients, e.g. cardiac, renal, glycemic issue
- ▶ Mirtazapine – however remember that sedation is in 57% of patients and weight gain is 17% - many practitioners like it, renally dosed, at higher doses is energizing
- ▶ Venlafaxine: May increase BP. Often a very good choice
  - ▶ Clinical pearl – Use XR formulation, IR can cause nausea
- ▶ Bupropion – Use to increase energy and **curtail** appetite, caution if seizure risk



# Choosing antidepressants continued

To avoid:

- ▶ Paroxetine: More sedating than other SSRIs, has anticholinergic effects, and, like some other SSRIs, can inhibit hepatic cytochrome P-450 2D6 enzyme activity, possibly impairing the metabolism of several drugs.
- ▶ TCAs : Highly anticholinergic and sedating and cause orthostatic hypotension; avoid.

Alternatives:

Methylphenidate – may be used in treatment resistant apathy and low energy – use in low doses before breakfast and lunch



# Agitation in Geriatrics

- ▶ According to BEERS Criteria - Antipsychotics should be used only for psychosis.
- ▶ Treatment depends on the underlying cause of the psychosis.
- ▶ 1<sup>st</sup> Intervention should be environmental and behavioral.
  1. Decrease stimulation
  2. Remove objects in room that could be used as weapons.
  3. Use relaxation techniques.
  4. Treat all treatable causes – polypharmacy, pain, hunger, depression



# Agitation and geriatrics

15

- ▶ Avoid antipsychotics for behavioral problems in the elderly with dementia until nonpharmacological attempts have failed, and the patient is a threat to themselves or others.
- ▶ **Acute** psychosis or agitation: Low dose haldol.
- ▶ Antipsychotics – started at  $\frac{1}{4}$  to  $\frac{1}{2}$  the usual starting dose
- ▶ Titration – *Slowly* up to the lowest dosage associated with clinical response.
- ▶ AIMS Scale: Every 6 months.
- ▶ Attempt to taper and discontinue within 4 months
- ▶ Closely monitor for recurrence of symptoms for at least 4 months post discontinuation.



# Side effects of antipsychotics in geriatric patients.

- ▶ Increased risk of cerebrovascular accident (stroke) and mortality in persons with dementia from 2.2 → 4.1%
- ▶ May exacerbate or cause syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; need to monitor sodium level closely when starting or changing dosages in older adults due to increased risk
- ▶ In nonpsychotic, agitated patients, antipsychotics control symptoms only marginally better than placebo and can have severe adverse effects.
- ▶ High-risk of NMS in Parkinson's/Lewy Body Dementia
- ▶ Black-box warning about using antipsychotics for dementia-related psychosis
- ▶ Risk/benefit – does it keep the patient home longer?



# Benzodiazepines

In a word – DON'T



# A national addiction?

18

- ▶ 2015: First US national Benzo prescription epidemiology study, used 2008 sample to estimate 75 million Rxs
- ▶ However, national rate of use for age 65-80 Men (6.1%) and Women (10.8%) despite many warnings about use in elderly – mostly from non-psychiatrist providers
- ▶ Highest rate of use (11.9%) observed among 80-year-old women
- ▶ Mean tx episode ranged from 224.9 days in young adults to 245.4 days in elderly
- ▶ **Across all age and sex groups <10% were getting Rx from a psychiatrist, esp. 65-80 year olds (3.6%)**

(Olfson, King, & Schoenbaum, 2015)




# Common Misuses

- ▶ ANYTHING over 4 weeks
- ▶ **Delirium** (which is around 1/2 of general inpatient agitation cases)
- ▶ **Geriatric** (see Beers Criteria)
- ▶ **GAD** (indicated, but don't do it)
- ▶ **Insomnia**
- ▶ **PTSD** (doesn't work...really!)
- ▶ **Panic Attacks**



# Adverse Effects



Tannenbaum, C., Martin, P., Tamblyn, R., Benedetti, A., & Ahmed, S. (2014)



5.5 million American have Alzheimer's  
One in 10 adults 65+  
Women > Men 2:1  
African-Americans > Whites 2:1  
5<sup>th</sup> Leading cause of death age 65+

And don't forget...there are other  
dementias



# Major Neurocognitive Disorder- Formerly known as Dementia

## Alzheimer's

"Plaques" Misshapen Beta-Amyloid deposits

"Tangles" misshapen Tau

Thought to attack the Acetylcholine circuits in the brain which has implications in Memory and learning

- Avoid anticholinergic meds
- Acetylcholinesterase Inhibitors – Slow for 6-12 months but do not stop progression
- NMDA antagonist also slows dementia - Memantine

## Lewy body

Lewy bodies destroy Dopaminergic neurons

- In the Substantia Nigra causes Parkinsons Disease
- In the cortex causes Lewy Body Dementia/ Parkinsons Dementia
- Treat with Parkinson Agents and/or refer

## Vitamin B/Folate

- May indicate longterm malnutrition
- Replete Vitamin and/or folate, also recommend Thiamine

## Frontemporal

- Usually earlier onsite
- Sudden personality/behavior change – impulsive/aggressive
- No treatments as of yet, aim for symptomatic relief
- Refer to memory clinic

## Vascular

- Stair step Progress
- Treat vascular symptoms, cognitive rehab, manage diabetes, BP
- Refer to memory clinic



# Dementia

- ▶ Concern for safety in the house (leaving things on the stove)
- ▶ Refer to a specialty clinic (e.g. CNADC at NMH or most major hospitals)
- ▶ **The Alzheimers Foundation has Case Managers free of charge that will help patients and families navigate the care system and help both patients and caregivers**



- ▶ Campanelli, C. M. (2012). American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults: The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. *Journal of the American Geriatrics Society*, 60(4), 616–631. <http://doi.org/10.1111/j.1532-5415.2012.03923.x>
- ▶ Fried, T. R., O'Leary, J., Towle, V., et al. Health outcomes associated with polypharmacy in community-dwelling older adults: A systematic review. *Journal of the American Geriatrics Society* 2014; 62:2261–2272.
- ▶ George, J, Phun YT, Bailey MJ et al. Development and validation of the Medication Regimen Complexity Index. *The Annals of Pharmacotherapy* 2004; 38:1369–1376
- ▶ Karel, M. J., Gatz, M., & Smyer, M. A. (2012). Aging and mental health in the decade ahead: What psychologists need to know. *American Psychologist*, 67(3), 184-198. doi:10.1037/a0025393
- ▶ Institute of Medicine (US) Committee on the Long-Run Macroeconomic Effects of the Aging U.S. Population. *Aging and the Macroeconomy: Long-Term Implications of an Older Population*. Washington (DC): National Academies Press (US); 2012 Dec 10. 3, Demographic Trends. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK148831/>
- ▶ Marengoni, A., Angleman, S., Melis, R., et al. Aging with multimorbidity: A systematic review of the literature. *Ageing Research Reviews* 2011; 10:430–439



- National Medical Directors Institute. (2017). *The Psychiatric Shortage Causes and Solutions*(Rep.). Washington, DC: National Council for Behavioral Health. [https://www.thenationalcouncil.org/wp-content/uploads/2017/03/Psychiatric-Shortage\\_National-Council-.pdf](https://www.thenationalcouncil.org/wp-content/uploads/2017/03/Psychiatric-Shortage_National-Council-.pdf)
- Olfson M, King M, Schoenbaum M. Benzodiazepine Use in the United States. *JAMA Psychiatry*. 2015; 72(2):136-142. doi:10.1001/jamapsychiatry.2014.1763.
- Reynolds, K., Pietrzak, R. H., El-Gabalawy, R., Mackenzie, C. S., & Sareen, J. (2015). Prevalence of psychiatric disorders in U.S. older adults: findings from a nationally representative survey. *World Psychiatry*, 14(1), 74–81. <http://doi.org/10.1002/wps.20193>
- US Preventive Services Task Force. Screening for depression: recommendations and rationale. *Ann Intern Med*. 2002;136(10):760-764 Website: [http://www.icsi.org/depression\\_5/depression\\_major\\_in\\_adults\\_in\\_primary\\_care\\_3.html](http://www.icsi.org/depression_5/depression_major_in_adults_in_primary_care_3.html)
- Violence Prevention. (2016, July 19). Retrieved October 03, 2017, from [https://www.cdc.gov/violenceprevention/suicide/statistics/Suicide Statistics](https://www.cdc.gov/violenceprevention/suicide/statistics/Suicide%20Statistics)
- World Health Organization (2017) Depression and Other Common Mental Disorders: Global Health Estimates. retrieved from <http://apps.who.int/iris/bitstream/10665/254610/1/WHO-MSD-MER-2017.2-eng.pdf?ua=1> on September 25, 2017
- Wimmer, B. C., Cross, A. J., Jokanovic, N., et al. Clinical Outcomes Associated with Medication Regimen Complexity in Older People: A Systematic Review. *Journal of the American Geriatrics Society* 2017; 65(4):747-753
- Yap, A. F., Thirumoorthy, T., Kwan, Y. H. Systematic review of the barriers affecting medication adherence in older adults. *Geriatric Gerontology International* 2016;16: 1093–1101.